After a 10-year project and a £60 million (US$80 million) investment, the UK Biobank has completed the whole body scans of 100,000 volunteers and is making the 1 billion images available for ...

Biocon Biologics, a subsidiary of biopharmaceutical company Biocon, said on Wednesday that the US Food and Drug Administration (FDA) has approved Kirsty (Insulin Aspart), the “first and only” ...

Automated insulin delivery systems improve life expectancy and are highly cost-effective for people with type 1 diabetes.

Biocon Biologics has received USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog Insulin Aspart for diabetes treatment. Intended to improve glycemic control in individuals with ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon announced that US FDA has approved Kirsty (insulin aspart-xjhz), 100 units/mL as the first and only ...

Biocon Biologics is a global leader in biosimilars and insulin production and is among the top three global players for rh- Insulin and Insulin Glargine, providing over 9.2 billion doses of insulin ...

The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with post-traumatic stress disorder (PTSD) ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz, as a 3 mL single-patient-use prefilled pen and 10 mL multiple-dose ...

The FDA approval of KIRSTY expands Biocon Biologics' biosimilar insulin portfolio, which also includes the first approved interchangeable biosimilar, Semglee® (Insulin Glargine-yfgn Injection).

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of ...